Clinical & Mechanistic Insights From Phase 2a Studies with Optimized Consortia Therapeutic MH002 in Ulcerative Colitis & Pouchitis as Basis for Future Pipeline Development
Time: 8:30 am
day: Conference Day One
Details:
- MH002, a 6-strain consortia therapeutic designed, optimized and manufactured through MRM Health’s CORAL® technology, is the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis
- Receive integrated insight on the translation of the mechanism of action of MH002 in activity in both Ulcerative Colitis and Pouchitis patients
- Explore how insights from different clinical studies can lead to synergistic and accelerated pipeline development
